Core Viewpoint - The company proposes to spin off its subsidiary, Xiansheng Zaiming, for an independent listing of H-shares on the Hong Kong Stock Exchange, which has been confirmed by the exchange [1] Group 1: Spin-off Details - The spin-off of Xiansheng Zaiming's H-shares will be conducted in accordance with the application guidelines of the company [1] - The company plans to submit a listing application form (A1 form) to the Hong Kong Stock Exchange on January 9, 2026, for the approval of Xiansheng Zaiming's H-shares [1] - Following the proposed spin-off and listing, the company expects to retain over 50% ownership of Xiansheng Zaiming, which will remain a subsidiary [1] Group 2: Company Profile - Xiansheng Zaiming is a biopharmaceutical company at the forefront of global drug innovation, focusing on the research, development, and commercialization of innovative oncology drugs, excluding those related to cell therapy and gene diagnosis and treatment technologies [1]
先声药业(02096)拟分拆先声再明的H股在联交所主板独立上市